Transplantation

A Prospective, Observational Study of Conversion From Immediate- to Prolonged-Release Tacrolimus in Renal Transplant Recipients in France: The OPALE Study

BACKGROUND: Potential benefits of once-daily, prolonged-release tacrolimus over the immediate-release formulation include improved adherence to immunosuppressives post transplantation. An observational study was performed to characterize real-world practice surrounding conversion from immediate- to prolonged-release tacrolimus in kidney transplant recipients.
MATERIAL AND METHODS: We performed a prospective, observational study of renal transplant recipients converted from immediate- to prolonged-release tacrolimus capsules. Conversion took place at the baseline visit, within the first 6 months of transplantation (early conversion group) or between 6 and 12 months of transplantation (late conversion group). Data collection was performed at routine follow-up at 6 and 12 months. Endpoints included conversion ratio from immediate- to prolonged-release tacrolimus, reasons for conversion, additional visits due to conversion, safety, and tolerability.

Valérie Moal, Philippe Grimbert, Adrien Beauvais, Laurence Dubel, Yann Le Meur
Sep 2019 – Annals of Transplantation

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Conversion d’une cohorte de patients transplantés rénaux du Tacrolimus en deux prises par jour (PrografTM) au Tacrolimus en une prise par jour (AdvagrafTM) : Analyse intermédiaire à 6 mois d’une étude française observationnelle multicentrique (OPALE)
Transplantation

Conversion d’une cohorte de patients transplantés rénaux du Tacrolimus en deux prises par jour (PrografTM) au Tacrolimus en une prise par jour (AdvagrafTM) : Analyse intermédiaire à 6 mois d’une étude française observationnelle multicentrique (OPALE)

Étude de suivi en conditions réelles de traitement des patients pris en charge par déférasirox
Transplantation

Étude de suivi en conditions réelles de traitement des patients pris en charge par déférasirox

Comparison of Efficacy and Safety of Cyclosporine (CsA) Discontinuation with Introduction of Sirolimus (SRL) at Week 12 to Standard Strategy in Renal Transplant Recipients Receiving Mycophenolate Mofetil (MMF)
Transplantation

Comparison of Efficacy and Safety of Cyclosporine (CsA) Discontinuation with Introduction of Sirolimus (SRL) at Week 12 to Standard Strategy in Renal Transplant Recipients Receiving Mycophenolate Mofetil (MMF)